Targets › WT1
6 programs from 6 companies in 7 trials: 6 Phase 1, 1 Phase 3; Oncology; next expected readout Nov 2026.
Transcription factor that plays an important role in cellular development and cell survival. Recognizes and binds to the DNA sequence 5'-GCG(T/G)GGGCG-3'. Regulates the expression of numerous target genes, including EPO. Plays an essential role for development of the urogenital system. (UniProt, P19544)
Open in Phaseline: the race on WT1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Sellas Life Sciences Group | Galinpepimut-S Wilms tumor protein vaccine antigen | WT1 | Phase 3 | Acute Myeloid Leukemia | Dec 2026 |
| Catherine Bollard | Tumor associated antigen lymphocytes (TAA-T) Multi-antigen specific cytotoxic T lymphocytes targeting WT1, PRAME, and SURVIVIN | WT1, PRAME, SURVIVIN | Phase 1 | Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS; Brain Tumor | Nov 2026 |
| David Reardon, MD | CUE-102 WT1-pHLA-IL2-Fc fusion protein; immuno-oncology therapeutic presenting WT1-derived peptide | WT1 | Phase 1 | Recurrent Glioblastoma | Jan 2027 |
| University Hospital, Antwerp | WT1/DC vaccine Dendritic cell vaccination with WT1 tumor antigen | WT1 | Phase 1 | Malignant Pleural Mesothelioma | Oct 2027 |
| Inovio Pharmaceuticals | INO-5401 DNA plasmid encoding WT1, PSMA, and hTERT tumor-associated antigens | WT1, PSMA, HGNC | Phase 1 | Glioblastoma | Dec 2027 |
| Fred Hutchinson Cancer Center | Autologous HLA-A*02:01-restricted CD4+/CD8+ Anti-WT1 TCR/CD8ab-expressing T-cell WT1-specific TCR-engineered T cell therapy | WT1 | Phase 1 | Acute Myeloid Leukemia | Jul 2030 |
Acute Myeloid Leukemia (2) Recurrent Glioblastoma (1) Malignant Pleural Mesothelioma (1) Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS (1) Brain Tumor (1) Glioblastoma (1)
mixed (4), protein or peptide (2)
Fred Hutchinson Cancer Center (1) David Reardon, MD (1) University Hospital, Antwerp (1) Catherine Bollard (1) Inovio Pharmaceuticals (1) Sellas Life Sciences Group (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.